Malik, Kunal

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Guttman-Yassky, E., Brunner, P. M., Neumann, A. U., Khattri, S., Pavel, A. B., Malik, K., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., et al. (2018) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 343

Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis

Zhou, L., Leonard, A., Pavel, A. B., Malik, K., Raja, A., Glickman, J., Estrada, Y. D., Peng, X., del Duca, E., Sanz-Cabanillas, J., et al. (2019) · Journal of Allergy and Clinical Immunology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 146

A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis

Simpson, E. L., Imafuku, S., Poulin, Y., Ungar, B., Zhou, L., Malik, K., Wen, H.-C., Xu, H., Estrada, Y. D., Peng, X., et al. (2019) · Journal of Investigative Dermatology

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 120

The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease

Brunner, P. M., He, H., Pavel, A. B., Czarnowicki, T., Lefferdink, R., Erickson, T., Canter, T., Puar, N., Rangel, S. M., Malik, K., et al. (2019) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 109